The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
Open accessAbstract
BACKGROUND: BRCA1/2 mutation carriers and women from a hereditary breast(/ovarian) cancer family have a highly increased risk of developing breast cancer (BC). Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce. METHODS: From 358 high-risk women (including 236 BRCA1/2 carriers) undergoing PM between 1994 and 2004, relevant data on the occurrence of BC in relation to PM, complications in relation to breast reconstruction (BR), mutation status, age at PM and preoperative imaging examination results were extracted from the medical records, and analyzed separately for women without (unaffected, n = 177) and with a BC history (affected, n = 181). RESULTS: No primary BCs occurred after PM (median follow-up 4.5 years). In one previously unaffected woman, metastatic BC was detected almost 4 years after PM (primary BC not found). Median age at PM was younger in unaffected women (P < .001), affected women more frequently were 50% risk carriers (P < .001). Unexpected (pre)malignant changes at PM were found in 3% of the patients (in 5 affected, and 5 unaffected women, respectively). In 49.6% of the women opting for BR one or more complications were registered, totaling 215 complications, leading to 153 surgical interventions (71%). Complications were mainly related to cosmetic outcome (36%) and capsular formation (24%). CONCLUSIONS: The risk of developing a primary BC after PM remains low after longer follow-up. Preoperative imaging and careful histological examination is warranted because of potential unexpected (pre)malignant findings. The high complication rate after breast reconstruction mainly concerns cosmetic issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The observation that the number of unaffected women significantly exceeded that of the affected women, whereas the number of women having undergone PM at our institution consists of about 50% affected women [26], supports the idea that selection bias for referral to the psychologist has indeed occurred.”
From Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy (2009) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766 · cited 5×
“09 Necrosis 11 (26) 4 (13) Bleeding 20 (48) 12 (39) Prosthesis luxation 2 (5) 0 (0) Poor arterial inflow 0 (0) 1 (3) Pneumothorax 1 (2) 0 (0) Late complications Surgery due to late complication No 11 (13) 7 (12) .”
InfluentialThe risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399 · cited 4×
“001 Death due to cancer 0 (0) 1 (3) 9 (10) 7 (8) Age at PM (years) Median 36.”
InfluentialBreast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229 · cited 4×
“33 Necrosis 1 (1) 3 (5) Capsular formation 31 (37) 20 (35) Prosthesis luxation 2 (2) 3 (5) Poor cosmetic appearance d 31 (37) 19 (34) Dog ear 16 (19) 12 (21)”
InfluentialRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H. L., Tilanus‐Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,686 · cited 2×
“74 Late (>6 weeks after BR) 85 (67) 57 (65) Surgery due to late complication No 38 (30) 24 (27) .”
Self-citationEfficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428 · cited 2×
“001 Death due to cancer 0 (0) 1 (3) 9 (10) 7 (8) Age at PM (years) Median 36.”
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · cited 2×
“11 At PM 35 (42) 1 (33) 16 (26) 5 (42) After PM 30 (36) 0 (0) 31 (51) 1 (8) Ovarian cancer before PM 4 (3) 0 (0) 2 (2) 1 (1) Unexpected (p)MF at PM 3 (2) 2 (6) 4 (4) 1 (1) Cancer after PM Breast cancer 1 (1) 0 (0) 0 (0) 0 (0) Ovarian cancer 2 (1) 0 (0) 1 (1) 0 (0)”
Kuhl, C. K., Schrading, S., Leutner, C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W. C., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,148 · cited 2×
“001 30–39 years 88 (50) 48 (27) 40–49 years 46 (26) 69 (38) ‡50 years 22 (12) 56 (31) PBSO Yes 86 (49) 73 (40) .”
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 3×
“33 Necrosis 1 (1) 3 (5) Capsular formation 31 (37) 20 (35) Prosthesis luxation 2 (2) 3 (5) Poor cosmetic appearance d 31 (37) 19 (34) Dog ear 16 (19) 12 (21)”
Self-citationEfficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743 · cited 1×
“001 Range 22–65 28–55 25–65 26–68 <30 years 18 (12) 3 (9) 6 (7) 2 (2) <.”
Cited by
Sorted by citations
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA -Related Cancer
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M. D., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.10987 · Cited by 487
Paluch–Shimon, S., Cardoso, F., Sessa, C., Balmañà, J., Cardoso, M. J., Gilbert, F. J., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 400
Risk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 270
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 254
Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 190
“Prophylactic bilateral mastectomy reduces the risk of breast cancer by almost 100% in mutation carriers [63, 116].”
BackgroundBRCA mutations in the management of breast cancer: the state of the art
Narod, S. A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.166 · Cited by 160
“The Netherlands is notable for a very high uptake of preventive mastectomy among gene carriers”
BackgroundRisk Assessment, Genetic Counseling, and Genetic Testing forBRCA-Related Cancer in Women
Nelson, H. D., Pappas, M., Cantor, A. G., Haney, E. M., & Holmes, R. S. (2019) · JAMA · doi:10.1001/jama.2019.8430 · Cited by 156
Gahm, J., Wickman, M., & Brandberg, Y. (2010) · The Breast · doi:10.1016/j.breast.2010.05.003 · Cited by 146
Yao, K. A., Liederbach, E., Tang, R., Lei, L., Czechura, T., Sisco, M., Howard, M. A., Hulick, P. J., Winchester, D. J., Coopey, S. B., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3883-3 · Cited by 130
“9 %,(16,19) and 3 %.(17) For non-BRCA1/2 carriers the rates were 0.”
Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
Larsen, M. J., Thomassen, M., Gerdes, A., & Kruse, T. A. (2014) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s18715 · Cited by 126
Skytte, A., Gerdes, A., Andersen, M., Sunde, L., Brøndum‐Nielsen, K., Waldstrøm, M., Kølvraa, S., & Crüger, D. G. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01329.x · Cited by 118
“A Dutch study has similar observations (18) while Metcalfe has no data for this decade, but has found the highest uptake of 20% in the age group between 35 and 60 (33).”
MethodGopie, J. P., Mureau, M. A. M., Seynaeve, C., ter Kuile, M. M., Menke‐Pluymers, M. B. E., Timman, R., & Tibben, A. (2012) · Familial Cancer · doi:10.1007/s10689-012-9588-5 · Cited by 118
Self-citationDeterminants of optimal mastectomy skin flap thickness
Robertson, S. A., Rusby, J. E., & Cutress, R. (2014) · British journal of surgery · doi:10.1002/bjs.9470 · Cited by 102
RANKL and RANK: From Mammalian Physiology to Cancer Treatment
Rao, S., Cronin, S. J. F., Sigl, V., & Penninger, J. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.001 · Cited by 95
Kaas, R., Verhoef, S., Wesseling, J., Rookus, M., Oldenburg, H., Peeters, M., & Rutgers, E. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c3c36d · Cited by 92
Risk reducing mastectomy: outcomes in 10 European centres
Evans, D. G., Baildam, A. D., Anderson, E. D. C., Brain, A., Shenton, A., Vasen, H. F. A., Eccles, D., Lucassen, A., Pichert, G., Hamed, H., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.062232 · Cited by 86
“updated their follow-up on 358 women undergoing RRM (177 in unaffected bilateral cases) in BRCA1/2 carriers.(21) Although no”
BackgroundSurveillance of prophylactic mastectomy
McLaughlin, C. C., Lillquist, P. P., & Edge, S. B. (2009) · Cancer · doi:10.1002/cncr.24623 · Cited by 83
“Bilateral prophylactic mastectomy has been shown to dramatically reduce the development of breast cancer in high-risk women.(3-8) Breast cancer forms only rarely in the residual breast epithelium regardless of the type of mastectomy performed (total mastectomy including the nipple vs subcutaneous or nipple-sparing mas…”
BackgroundHereditary lobular breast cancer with an emphasis on E-cadherin genetic defect
Corso, G., Figueiredo, J., Vecchia, C. L., Veronesi, P., Pravettoni, G., Macis, D., Karam, R., Gullo, R. L., Provenzano, E., Toesca, A., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105337 · Cited by 87
Haggar, F. A., Pereira, G. F., Preen, D. B., Holman, C. D. J., & Einarsdóttir, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113292 · Cited by 83
Cobain, E. F., Milliron, K. J., & Merajver, S. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.001 · Cited by 88
Hunt, K. K., Euhus, D., Boughey, J. C., Chagpar, A. B., Feldman, S. M., Hansen, N. M., Kulkarni, S., McCready, D. R., Mamounas, E. P., Wilke, L. G., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5688-z · Cited by 82
Hoskins, P. J., & Gotlieb, W. H. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21408 · Cited by 77
Yao, K. A., Winchester, D. J., Czechura, T., & Huo, D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2745-1 · Cited by 77
Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery
Salhab, M., Bismohun, S., & Mokbel, K. (2010) · BMC Women s Health · doi:10.1186/1472-6874-10-28 · Cited by 70
Chiba, A., Hoskin, T. L., Hallberg, E. J., Cogswell, J. A., Heins, C. N., Couch, F. J., & Boughey, J. C. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5328-7 · Cited by 70
“Similarly, Heemskerk-Gerritsen et al.27 reported a lower mortality rate for BRCA mutation patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy than for the surveillance group (9.6 and 21.6 per 1000 person-years of observation, respectively; adjusted HR 0.19; 95 % CI 0.29–0.82).”
BackgroundInfluentialBreast cancer after bilateral risk-reducing mastectomy
Skytte, A., Crüger, D. G., Gerster, M., Lænkholm, A., Lang, C., Brøndum‐Nielsen, K., Andersen, M., Sunde, L., Kølvraa, S., & Gerdes, A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01604.x · Cited by 66
High-throughput functional evaluation of BRCA2 variants of unknown significance
Ikegami, M., Kohsaka, S., Ueno, T., Momozawa, Y., Inoue, S., Tamura, K., Shimomura, A., Hosoya, N., Kobayashi, H., Tanaka, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16141-8 · Cited by 67
Women’s motives to opt for either implant or DIEP-flap breast reconstruction
Gopie, J. P., Hilhorst, M. T., Kleijne, A., Timman, R., Menke‐Pluymers, M. B. E., Hofer, S. O. P., Mureau, M. A. M., & Tibben, A. (2011) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2011.03.030 · Cited by 61
Self-citationBilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer
Arver, B. W., Isaksson, K., Atterhem, H., Baan, A., Bergkvist, L., Brandberg, Y., Ehrencrona, H., Emanuelsson, M., Hellborg, H., Henriksson, K. M., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e318214b55a · Cited by 61
Sermijn, E., Delesie, L. M., Deschepper, E., Pauwels, I., Bonduelle, M., Teugels, E., & Grève, J. D. (2016) · Familial Cancer · doi:10.1007/s10689-015-9854-4 · Cited by 61
“Mean (SD) [min–max] [18–77] [18–77] [18–75]”
Wang, N., Zheng, Y., Gu, J., Cai, Y., Wang, S., Zhang, F., Chen, J., Situ, H., Lin, Y. H., & Wang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-15030-3 · Cited by 60
Meiser, B., Tucker, K., Friedlander, M. L., Barlow-Stewart, K. K., Lobb, E. A., Saunders, C. M., & Mitchell, G. (2008) · Breast Cancer Research · doi:10.1186/bcr2194 · Cited by 58
Gahm, J., Edsander-Nord, Å., Jurell, G., & Wickman, M. (2010) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e3181ef8b01 · Cited by 53
Overview of indications for nipple sparing mastectomy
Tousimis, E. A., & Haslinger, M. L. (2018) · Gland Surgery · doi:10.21037/gs.2017.11.11 · Cited by 53
“Incidental cancers reported for BRCA1/2 carriers in other series ranged from 0% (4,5) to 3% (4,6-8).”
BackgroundGahm, J., Jurell, G., Edsander-Nord, Å., & Wickman, M. (2008) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2008.11.014 · Cited by 52
A systematic review of men's experiences of their partner's mastectomy: coping with altered bodies
Rowland, E., & Metcalfe, A. (2014) · Psycho-Oncology · doi:10.1002/pon.3556 · Cited by 51
“For some women, this choice is not an option, and they have to undergo a mastectomy to treat the cancer or to remove the risk of it, with between 31% and 51% of women carrying a BRCA gene mutation, opting for a prophylactic bi-lateral or contra-lateral mastectomy [4,5].”
BackgroundResidual Breast Tissue after Mastectomy: How Often and Where Is It Located?
Griepsma, M., van Zuidewijn, D. B. W. D. R., Grond, A. J. K., Siesling, S., Groen, H., & de Bock, G. H. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3383-x · Cited by 49
Radiotherapy in the Treatment of Hereditary Breast Cancer
Pierce, L. J., & Haffty, B. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.08.008 · Cited by 50
Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics
Julian‐Reynier, C., Bouhnik, A., Mouret-Fourme, E., Gauthier‐Villars, M., Berthet, P., Lasset, C., Fricker, J., Caron, O., Gesta, P., Luporsi, É., et al. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181f48d1c · Cited by 46
Pal, T., & Vadaparampil, S. T. (2012) · Cancer Control · doi:10.1177/107327481201900402 · Cited by 44
Flippo-Morton, T. S., Walsh, K. K., Chambers, K. M., Amacker-North, L., White, B., Sarantou, T., Boselli, D. M., & White, R. L. (2015) · The Breast Journal · doi:10.1111/tbj.12521 · Cited by 42
High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study
Wasteson, E., Sandelin, K., Brandberg, Y., Wickman, M., & Arver, B. W. (2010) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2010.01204.x · Cited by 36
Borreani, C., Manoukian, S., Bianchi, E., Brunelli, C., Peissel, B., Caruso, A., Morasso, G., & Pierotti, M. A. (2014) · Clinical Genetics · doi:10.1111/cge.12298 · Cited by 38
“The principal reason for choosing prophylactic bilateral mastectomy (PBM) is to reduce the risk of contracting a life-threatening disease, and some studies show that no regrets regarding this choice were found (17, 18).”
BackgroundCardiovascular risk of BRCA1/2 mutation carriers: A review
van Westerop, L., Jong, M. A.-D., Hoogerbrugge, N., de Hullu, J. A., & Maas, A. H. E. M. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.06.012 · Cited by 36
Elsayegh, N., Webster, R. D., Gutierrez‐Barrera, A. M., Lin, H. Y., Kuerer, H. M., Litton, J. K., Bedrosian, I., & Arun, B. (2018) · Cancer Medicine · doi:10.1002/cam4.1519 · Cited by 34
Hereditary breast cancer: from bench to bedside
Grève, J. D., Sermijn, E., Brakeleer, S. D., Ren, Z., & Teugels, E. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283139173 · Cited by 32
Genetic Predisposition Syndromes and Their Management
Euhus, D., & Robinson, L. D. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2013.01.005 · Cited by 36
Heijer, M. D., van Asperen, C. J., Harris, H. J., Nippert, I., Schmidtke, J., Bouhnik, A., Julian‐Reynier, C., Evans, D. G., & Tibben, A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.025 · Cited by 31
Management of breast cancer risk inBRCA1/2mutation carriers who are unaffected with cancer
Collins, J. M., & Isaacs, C. J. (2020) · The Breast Journal · doi:10.1111/tbj.13970 · Cited by 28
Crotser, C. B., & Boehmke, M. M. (2009) · Journal of Cancer Survivorship · doi:10.1007/s11764-008-0077-7 · Cited by 28
“Several women required reoperations due to complications with reconstruction [45].”
BackgroundTan, M. B., Bleiker, E. M., Menke-Pluymers, M. B., Van Gool, A. R., van Dooren, S., Van Geel, B. N., Tilanus-Linthorst, M. M., Bartels, K. C., Klijn, J. G., Brekelmans, C. T., et al. (2009) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-7-6 · Cited by 27
“The observation that the number of unaffected women significantly exceeded that of the affected women, whereas the number of women having undergone PM at our institution consists of about 50% affected women [26], supports the idea that selection bias for referral to the psychologist has indeed occurred.”
ResultSelf-citationPichert, G., Jacobs, C., Jacobs, I. J., Menon, U., Manchanda, R., Johnson, M., Hamed, H., Firth, C., Evison, M., Tutt, A. N. J., et al. (2010) · Familial Cancer · doi:10.1007/s10689-010-9333-x · Cited by 24
“[12], while RRSO can reduce ovarian/fallopian tube cancer risk by 95% and breast cancer risk by up to 50% in premenopausal women Rebbeck et al.”
BackgroundElsayegh, N., Kuerer, H. M., Lin, H. Y., Gutierrez‐Barrera, A. M., Jackson, M., Muse, K. I., Litton, J. K., Albarracin, C. T., Afrough, A., Hortobágyi, G. N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3747-x · Cited by 23
“Tuttle’s findings also show that DCIS patients younger than 40 years were significantly associated with increased rates of CPM in their cohort.2 Moreover, Heemskerk-Gerritsen et al.18 found that prophylactic mastectomy was more prevalent among younger affected (with a history of BC) and/or unaffected women between 37…”
Wong, S. M., Ferroum, A., Apostolova, C., Alhassan, B., Prakash, I., Basik, M., Boileau, J. F., Meterissian, S. H., Aleynikova, O., Wong, N., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11916-3 · Cited by 23
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers
Schackmann, E. A., Muñoz, D. F., Mills, M. A., Plevritis, S. K., & Kurian, A. W. (2012) · Familial Cancer · doi:10.1007/s10689-012-9577-8 · Cited by 21
“These high-risk women can address their cancer predisposition with strategies including prophylactic mastectomy (PM) [3–5], prophylactic bilateral salpingo-oophorectomy (PO) [5–9], and intensive breast screening with annual mammography and magnetic resonance imaging (MRI) [10–15].”
BackgroundBommer, C., Lupatsch, J. E., Bürki, N., & Schwenkglenks, M. M. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01396-9 · Cited by 21
“Dissatisfaction was also related with surgical complications [74] which occurred in up to 64% of patients [13, 75, 76], and unanticipated secondary surgeries after PBM [75].”
BackgroundPostoperative Outcomes of Pre-Pectoral Versus Sub-Pectoral Implant Immediate Breast Reconstruction
Houvenaeghel, G. F., Bannier, M., Bouteille, C., Tallet, C., Sabiani, L., Charavil, A., Bertrand, A., Troy, A. V., Buttarelli, M., Teyssandier, C., et al. (2024) · Cancers · doi:10.3390/cancers16061129 · Cited by 19
Hagen, A. I., Mæhle, L., Vedå, N., Høberg‐Vetti, H., Stormorken, A. T., Ludvigsen, T., Guntvedt, B., Isern, A. E., Schlichting, E., Kleppe, G., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.10.002 · Cited by 18
“5 years [6].”
Euhus, D., & Diaz, J. (2014) · The Breast Journal · doi:10.1111/tbj.12352 · Cited by 18
“5 0 2007 (39) Retrospective Familial 358 4.”
BackgroundManaging hereditary breast cancer risk in women with and without ovarian cancer
Peters, M. L. B., Garber, J. E., & Tung, N. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.013 · Cited by 18
Deutschmann, C., Singer, C. F., Gschwantler‐Kaulich, D., Pfeiler, G., Leser, C., Baltzer, P., Helbich, T. H., Kraus, C., Korbatits, R., Marzogi, A., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10764-y · Cited by 17
“mastectomy are located within the chest wall most commonly within the skin and subcutaneous tissue indicating an origin from RFGT, followed by recurrences within the pectoral muscle [3, 10].”
BackgroundHanley, G. E., McAlpine, J. N., Cheifetz, R. E., Schrader, K. A., McCullum, M., & Huntsman, D. D. (2019) · Current Oncology · doi:10.3747/co.26.4068 · Cited by 17
Murphy, A. I., Asadourian, P. A., Mellia, J. A., & Rohde, C. H. (2022) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009493 · Cited by 16
Euhus, D. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3906-0 · Cited by 16
Staněk, K., Zimovjanová, M., Suk, P., Jonas, F., Zimovjanová, A., Molitor, M., & Měšťák, O. (2021) · Aesthetic Plastic Surgery · doi:10.1007/s00266-021-02506-x · Cited by 16
Evaluation of Contralateral and Bilateral Prophylactic Mastectomy and Reconstruction Outcomes
Bletsis, P. P., Bucknor, A. E. M., Chattha, A. S., Kamali, P., Chen, A., Flecha‐Hirsch, R., van der Lei, B., Lee, B. T., & Lin, S. J. (2018) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000001358 · Cited by 14
Cragun, D. L., & Pal, T. (2013) · ISRN Oncology · doi:10.1155/2013/260847 · Cited by 14
Lapointe, J., Dorval, M., Chiquette, J., Joly, Y., Guertin, J. R., Laberge, M., Gekas, J., Hébert, J., Pomey, M., Mariño, T. C., et al. (2021) · Cancers · doi:10.3390/cancers13112729 · Cited by 13
“Bilateral mastectomy has been shown to decrease the risk of breast cancer by approximately 90% [15,16].”
BackgroundOseni, T. O., & Jatoi, I. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.04.010 · Cited by 13
Resource implications of risk-reducing mastectomy and reconstruction
Robertson, S. A., Summerhayes, C., Laws, S., & Rainsbury, R. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.10.002 · Cited by 12
Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery
Magnoni, F., Sacchini, V., Veronesi, P., Bianchi, B., Bottazzoli, E. I., Tagliaferri, V., Mazzotta, E., Castelnovo, G., Deguidi, G., Rossi, E. M. C., et al. (2022) · Cancers · doi:10.3390/cancers14133245 · Cited by 12
Rashdan, H. R. M., Abdelrahman, M. T., Luca, A. C. D., & Mangini, M. (2024) · Pharmaceuticals · doi:10.3390/ph17010088 · Cited by 11
Fakkert, I. E., Jansen, L., Meijer, K., Kok, T., Oosterwijk, J. C., Mourits, M. J. E., & de Bock, G. H. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1423-4 · Cited by 11
“Prophylactic mastectomy strongly reduces the breast cancer risk, with about 90% at the age of 70 when conducted at the age of 38 years [6, 7].”
BackgroundAlamouti, R., Hachach‐Haram, N., & Farhadi, J. (2015) · European Journal of Plastic Surgery · doi:10.1007/s00238-015-1086-1 · Cited by 11
Maarse, W., Jonasse, Y., Ausems, M. G. E. M., Schipper, M. E. I., & van Hillegersberg, R. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2009.03.006 · Cited by 10
Dietzel, F., Kolberg, L., Vesper, A., Hoffmann, J., Nestle-Krämling, C., Zwiefel, K., Friebe, V., Sawicki, L. M., Bruckmann, N. M., Jannusch, K., et al. (2023) · Cancers · doi:10.3390/cancers15030829 · Cited by 10
“Residual glandular tissue after risk-reducing mastectomy is associated with a risk of breast cancer that cannot be precisely determined [13,14].”
BackgroundSurgical Management of Hereditary Breast Cancer
Berger, E. R., & Golshan, M. A. (2021) · Genes · doi:10.3390/genes12091371 · Cited by 13
Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies
Mattos, D., Gfrerer, L., Ling, I. T. C., Reish, R. G., Hughes, K. S., Halpern, E. F., Cetrulo, C. L., Colwell, A. S., Winograd, J. M., Yaremchuk, M. J., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4896-2 · Cited by 10
Managing the Breast in Patients Who Test Positive for Hereditary Breast Cancer
Euhus, D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2258-x · Cited by 9
Koskenvuo, L. E., Svarvar, C., Suominen, S., Aittomäki, K., & Jahkola, T. (2013) · Scandinavian Journal of Surgery · doi:10.1177/1457496913490460 · Cited by 9
“(5), 94% of unaffected women opted for breast reconstruction.”
BackgroundInfluentialBernstein‐Molho, R., Friedman, E., & Evron, E. (2022) · Cancers · doi:10.3390/cancers14194592 · Cited by 8
Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy
Wong, S. M., Apostolova, C., Eisenberg, E., & Foulkes, W. D. (2024) · Current Oncology · doi:10.3390/curroncol31010023 · Cited by 8
“…cancer is dramatically lowered but not completely eliminated following bilateral RRM, with residual lifetime risk decreasing to approximately 1–2% [9–12]. dramatically lowered but not completely eliminated following bilateral RRM, with residual lifetime risk decreasing to approximately 1–2% [9–12].”
BackgroundBreast Cancer Prevention Across the Cancer Care Continuum
Klemp, J. R. (2015) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2015.03.002 · Cited by 9
Goodson, P. (2015) · Emerald Group Publishing Limited eBooks · doi:10.1108/s1057-629020150000016005 · Cited by 8
Prophylactic Mastectomy: An Appraisal
Zagouri, F., Chrysikos, D., Sergentanis, T. Ν., Γιαννακοπούλου, Γ., Zografos, C. G., PAPADIMITRIOU, C. A., & Zografos, G. (2013) · The American Surgeon · doi:10.1177/000313481307900233 · Cited by 6
The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers
Grossman, S. G. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10222 · Cited by 6
Ismail-Khan, R. R., Minton, S. E., & Khakpour, N. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1145-5_29 · Cited by 6
Local approaches to hereditary breast cancer.
Cooper, B., Murphy, J., Sacchini, V., & Formenti, S. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt327 · Cited by 6
“In one series of 358 high-risk women (236 with a BRCA mutation) undergoing prophylactic mastectomy, 177 had no prior history of breast cancer [35].”
BackgroundNew insights into the prevention and treatment of familial breast cancer
Euhus, D. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21664 · Cited by 5
Nipple-Sparing Mastectomy: To Spare Or Not To Spare?
Chiba, A., Jakub, J. W., & Hieken, T. J. (2016) · Current Surgery Reports · doi:10.1007/s40137-016-0138-1 · Cited by 5
“In a large BRCA cohort, non-NSM prophylactic mastectomy has been shown to be a very effective means of risk reduction in this high-risk population [32].”
Risk-Reducing Mastectomy for BRCA Gene Mutation Carriers
Euhus, D. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4537-9 · Cited by 5
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Mitchell, R. L., Buckingham, L. E., Cobleigh, M., Rotmensch, J., Burgess, K. R., & Usha, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195497 · Cited by 6
Genetic Issues in Patients with Breast Cancer
Fossland, V. S., Stroop, J., Schwartz, R. C., & Kurtzman, S. H. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.008 · Cited by 5
“Studies of women who are BRCA carriers suggest that carrier status and personal history of cancer are closely correlated with undergoing a prophylactic mastectomy.(28,64)”
BackgroundGandhi, A., Duxbury, P. J., Clancy, T., Lalloo, F. I., Wisely, J. A., Kirwan, C., Foden, P., Stocking, K., Howell, A., & Evans, D. G. (2022) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009383 · Cited by 4
Management of Women at High Familial Risk of Breast and Ovarian Cancer
Field, K., & Phillips, K. (2009) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781848163652_0039 · Cited by 4
Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers
Briasoulis, E. C., Ziogas, D. E., & Fatouros, M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9738-4 · Cited by 4
PPAC (programme personnalisé de l’après-cancer) : rationnel et mise en place
Gangler, A., Lesur, A., & Dalenc, F. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2595-7 · Cited by 3
“Deux autres séries ont cependant montré des résultats similaires avec une efficacité quasiment de 100 % sur le risque controlatéral [36,37].”
BackgroundThe genetics of breast cancer, risk-reducing surgery and prevention
Evans, D. G., Kwong, A., & Baildam, A. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4959-0.00008-4 · Cited by 3
BRCA1 and BRCA2 Mutations - Diagnostic and Therapeutic Implications
Valarmathi, M. T. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100842 · Cited by 2
Detection of the 5382insC mutation in the human BRCA1 gene with fluorescent labeled oligonucleotides
Mitrofanov, D. V., Chasovnikova, O. B., Коваленко, С. П., & Lyakhovich, V. V. (2009) · Molecular Biology · doi:10.1134/s002689330906003x · Cited by 3
Metadata
- Authors
- Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Seynaeve, Caroline
- Venue
- Annals of Surgical Oncology
- Published
- 2007-05-31
- Volume
- 14
- Issue
- 12
- Pages
- 3335-3344
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- PMC
- PMC2077910
- OpenAlex
- W2108830626
- Cited by
- 153
- References
- 38
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 7 · 2017: 7 · 2016: 11 · 2015: 9 · 2014: 14 · 2013: 14 · 2012: 6
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Annals of Surgical Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Surgery › Breast Implant and Reconstruction
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- prophylactic mastectomy, BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary breast cancer, breast reconstruction complications, capsular contracture, cosmetic outcome, preoperative imaging, breast cancer risk reduction, high-risk women
- MeSH terms
- Adult, Breast Neoplasms, Female, Follow-Up Studies, Humans, Longitudinal Studies, Mastectomy, Middle Aged, Mutation, Neoplasm Staging, Netherlands, Ovarian Neoplasms, Postoperative Complications, Prospective Studies, Retrospective Studies, Risk Factors, Cohort Studies, Incidence, Mammaplasty, Treatment Outcome, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
